Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve β-catenin and cyclin D1 down-regulation

Biochemical Pharmacology

Volumn 64, Issue 9, 2002, Pages 1325-1336

  Li, Han ^a   Liu, Li ^a   David, Mary L ^a   Whitehead, Clark M ^a   Chen, Ming ^a   Fetter, John R ^a   Sperl, Gerhard J ^a   Pamukcu, Rifat ^a   Thompson, W Joseph ^a  

^a Cell Pathways Inc   (United States)

Author keywords

Apoptosis; cGMP; Colon cancer; Cyclin D1; Familial adenomatous polyposis; Sulindac sulfone

Indexed keywords

1H INDENE 3 ACETAMIDE,5 FLUORO 2 METHYL N (PHENYLMETHYL) 1 [(3,4,5 TRIMETHOXYPHENYL)METHYLENE]; 5 FLUORO 2 METHYL(4 PYRIDYLIDENE) 3 (N BENZYL)INDENYLACETAMIDE; ACETAMIDE DERIVATIVE; AMINO ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN; CASPASE 3; CASPASE 3 INHIBITOR; CD 248; CP 461; CYCLIN D1; MESSENGER RNA; PROTEASOME; SULINDAC SULFONE; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; TIME;

ADENOMATOUS POLYPOSIS COLI; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CASPASE 3; CASPASES; COLONIC NEOPLASMS; CYCLIN D1; CYSTEINE ENDOPEPTIDASES; CYTOSKELETAL PROTEINS; DOWN-REGULATION; HUMANS; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; SULINDAC; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; UBIQUITIN;

EID: 0036830654     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01345-X     Document Type: Article

References (62)

1. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science. 287:2000;1606-1609.
2. Behrens J. Control of β-catenin signaling in tumor development. Ann. NY Acad. Sci. 910:2000;21-33.
3. Orford K., Crockett C., Jensen J.P., Weissman A.M., Byers S.W. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J. Biol. Chem. 272:1997;24735-24738.
4. Laney J.D., Hochstrasser M. Substrate targeting in the ubiquitin system. Cell. 97:1999;427-430.
5. Rubinfeld B., Albert I., Porfiri E., Fiol C., Munemitsu S., Polakis P. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science. 272:1996;1023-1026.
6. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 275:1997;1787-1790.
7. Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1998;1130-1134.
8. Thompson H.J., Jiang C., Lu J., Mehta R.G., Piazza G.A., Paranka N.S., Pamukcu R., Ahnen D.J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:1997;267-271.
9. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., Pamukcu R., Ahnen D.J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57:1997;2452-2459.
10. Lim J.T., Piazza G.A., Han E.K., Delohery T.M., Li H., Finn T.S., Buttyan R., Yamamoto H., Sperl G.J., Brendel K., Gross P.H., Pamukcu R., Weinstein I.B. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. 58:1999;1097-1107.
11. Liu L., Li H., Underwood T., Lloyd M., David M., Sperl G., Pamukcu R., Thompson W.J. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J. Pharmacol. Exp. Ther. 299:2001;583-592.
12. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B., Sperl G., Ahnen D., Pamukcu R. Exisulind induction of apoptosis involves guanosine 3′, 5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res. 60:2000;3338-3342.
13. Lawrence D.W., Pryzwansky K.B. The vasodilator-stimulated phosphoprotein is regulated by cyclic GMP-dependent protein kinase during neutrophil spreading. J. Immunol. 166:2001;5550-5556.
14. Ammendola A., Geiselhöringer A., Hofmann F., Schlossmann J. Molecular determinants of the interaction between the inositol 1, 4, 5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) and cGMP kinase Iβ J. Biol. Chem. 276:2001;24153-24159.
15. Butt E., Immler D., Meyer H.E., Kotlyarov A., Laass K., Gaestel M. Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J. Biol. Chem. 276:2001;7108-7113.
16. Shih I.-M., Yu J., He T.-C., Vogelstein B., Kinzler K.W. The β-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res. 60:2000;1671-1676.
17. Goss K.H., Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J. Clin. Oncol. 18:2000;1967-1979.
18. Polakis P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9:1999;15-21.
19. Iwamoto M., Ahnen D.J., Franklin W.A., Maltzman T.H. Expression of β-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis. 21:2000;1935-1940.
20. Ilyas M., Tomlinson I.P.M., Rowan A., Pignatelli M., Bodmer W.F. β-Catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 94:1997;10330-10334.
21. Morin P.J., Vogelstein B., Kinzler K.W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;7950-7954.
22. Park W.S., Oh R.R., Park J.Y., Lee S.H., Shin M.S., Kim Y.S., Kim S.Y., Lee H.K., Kim P.J., Oh S.T., Yoo N.J., Lee J.Y. Frequent somatic mutations of the β-catenin gene in intestinal-type gastric cancer. Cancer Res. 59:1999;4257-4260.
23. Sommers C.L., Gelmann E.P., Kemler R., Cowin P., Byers S.W. Alterations in β-catenin phosphorylation and plakoglobin expression in human breast cancer cells. Cancer Res. 54:1994;3544-3552.
24. Gamallo C., Palacios J., Moreno G., Calvo de Mora J., Suárez A., Armas A. β-Catenin expression pattern in stage I and II ovarian carcinomas: relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 155:1999;527-536.
25. Chan E.F., Gat U., McNiff J.M., Fuchs E. A common human skin tumour is caused by activating mutations in β-catenin. Nat. Genet. 21:1999;410-413.
26. Iwao K., Miyoshi Y., Nawa G., Yoshikawa H., Ochi T., Nakamura Y. Frequent β-catenin abnormalities in bone and soft-tissue tumors. Jpn. J. Cancer Res. 90:1999;205-209.
27. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5522-5527.
28. Tetsu O., McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:1999;422-426.
29. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene. 10:1995;775-778.
30. Kip1 and cyclin D1 expression in esophageal cancer. Oncology. 57:1999;311-317.
31. Lingfei K., Pingzhang Y., Zhengguo L., Jianhua G., Yaowu Z. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. Cancer Lett. 130:1998;93-101.
32. Bartkova J., Lukas J., Strauss M., Bartek J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer. 58:1994;568-573.
33. Arber N., Hibshoosh H., Moss S.F., Sutter T., Zhang Y., Begg M., Wang S., Weinstein I.B., Holt P.R. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 110:1996;669-674.
34. Arber N., Doki Y., Han E.K., Sgambato A., Zhou P., Kim N.H., Delohery T., Klein M.G., Holt P.R., Weinstein I.B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57:1997;1569-1574.
35. Sauter E.R., Nesbit M., Litwin S., Klein-Szanto A.J., Cheffetz S., Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res. 59:1999;4876-4881.
36. Chang W-CL, Pfeiffer GR, Everley LC, Clapper ML. Effect of sulindac sulfone on downstream targets of the adenomatous polyposis coli (APC) pathway in human colon carcinoma cells with defined mutations in APC and β-catenin. In: Proceedings of 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, USA, 1-5 April 2000. AACR: Cadmus Journal Services, 2000. p. 494.
37. McEntee M.F., Chiu C.-H., Whelan J. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis. 20:1999;635-640.
38. Mahmoud N.N., Boolbol S.K., Bilinski R.T., Martucci C., Chadburn A., Bertagnolli M.M. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res. 57:1997;5045-5050.
39. Steinhusen U., Badock V., Bauer A., Behrens J., Wittman-Liebold B., Dorken B., Bommert K. Apoptosis-induced cleavage of β-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J. Biol. Chem. 275:2000;16345-16353.
40. Kusama K., Jiang Y., Toguchi M., Ohno J., Shikata H., Sakashita H., Sakagami H. Use of the monoclonal antibody M30 for detecting HSG cell apoptosis. Anticancer Res. 20:2000;151-154.
41. Leers M.P.G., Kölgen W., Björklund V., Bergman T., Tribbick G., Persson B., Björklund P., Ramaekers F.C.S., Björklund B., Nap M., Jörnvall H., Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187:1999;567-572.
42. Liu L, Lloyd M, Pegram M, Slamon D, Pamukcu R, Thompson WJ. CP461 induces apoptosis and growth inhibition of breast cancer cells independent of HER2/neu receptor expression. Special Issue of Breast Cancer Research and Treatment, 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, USA, 6-9 December 2000. p. 94.
43. He T.-C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science. 281:1998;1509-1512.
44. El Bahrawy M.A., Pignatelli M. E-cadherin and catenins: molecules with versatile roles in normal and neoplastic epithelial cell biology. Microsc. Res. Tech. 43:1998;224-232.
45. Groden J., Joslyn G., Samowitz W., Jones D., Bhattacharyya N., Spirio L., Thliveris A., Robertson M., Egan S., Meuth M. Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Res. 55:1995;1531-1539.
46. Jeon S.H., Jeong S., Lee C., Kim J.K., Kim Y.S., Chung H.Y., Park S.D., Seong R.H. Expression of Tcf-1 mRNA and surface TCR-CD3 complexes are reduced during apoptosis of T cells. Int. Immunol. 10:1998;1519-1527.
47. He T.-C., Chan T.A., Vogelstein B., Kinzler K.W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99:1999;335-345.
48. Fukuda K. Apoptosis-associated cleavage of β-catenin in human colon cancer and rat hepatoma cells. Int. J. Biochem. Cell Biol. 31:1999;519-529.
49. Brancolini C., Lazarevic D., Rodriguez J., Schneider C. Dismantling cell-cell contacts during apoptosis is coupled to a caspase-dependent proteolytic cleavage of β-catenin. J. Cell Biol. 139:1997;759-771.
50. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
51. Wisdom R., Johnson R.S., Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 18:1999;188-197.
52. D'Amico M., Hulit J., Amanatullah D.F., Zafonte B.T., Albanese C., Bouzahzah B., Fu M., Augenlicht L.H., Donehower L.A., Takemaru K.-I., Moon R.T., Davis R., Lisanti M.P., Shtutman M., Zhurinsky J., Ben Ze'ev A., Troussard A.A., Dedhar S., Pestell R.G. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3β and cAMP-responsive element-binding protein-dependent pathways. J. Biol. Chem. 275:2000;32649-32657.
53. 1 phase. Biochem. J. 326:1997;61-68.
54. 2-terminal kinase 1. Clin. Cancer Res. 6:2000;4136-4141.
55. Rubinfeld B., Robbins P., El Gamil M., Albert I., Porfiri E., Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science. 275:1997;1790-1792.
56. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S., Murata M., Shimano T., Yamaoka Y., Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24:2000;245-250.
57. Webster M.T., Rozycka M., Sara E., Davis E., Smalley M., Young N., Dale T.C., Wooster R. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer. 28:2000;443-453.
58. Thompson W.J., Liu L., Li H., Fetter J., Sperl G., Piazza G.A., Pamukcu R. Exisulind induces apoptosis in colonic tumor cells lacking APC mutations by cyclic GMP mediated β-catenin reduction. Gastroenterology. 118:2000;A670.
59. Goluboff E.T., Shabsigh A., Saidi J.A., Weinstein I.B., Mitra N., Heitjan D., Piazza G.A., Pamukcu R., Buttyan R., Olsson C.A. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology. 53:1999;440-445.
60. Rao K.V., Detrisac C.J., Steele V.E., Hawk E.T., Kelloff G.J., McCormick D.L. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 17:1996;1435-1438.
61. Malkinson A.M., Koski K.M., Dwyer-Nield L.D., Rice P.L., Rioux N., Castonguay A., Ahnen D.J., Thompson H., Pamukcu R., Piazza G.A. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis. 19:1998;1353-1356.
62. Stoner G.D., Budd G.T., Ganapathi R., DeYoung B., Kresty L.A., Nitert M., Fryer B., Church J.M., Provencher K., Pamukcu R., Piazza G., Hawk E., Kelloff G., Elson P., van Stolk R.U. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv. Exp. Med. Biol. 470:1999;45-53.